Talking About Tumors with Ryann and Ryan - A medical oncology podcast

03_02 Localized Melanoma

April 14, 2023 Talking About Tumors Season 3 Episode 2
03_02 Localized Melanoma
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
More Info
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
03_02 Localized Melanoma
Apr 14, 2023 Season 3 Episode 2
Talking About Tumors

1. Background, staging and work-up of regional melanoma
2. Evidence for adjuvant and neoadjuvant immunotherapy
3. Adjuvant BRAF/MEK inhibitor 
4. Considerations for stage IIB/IIC disease

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:


1.           Patel SP et al. NEJM. 2023;388(9):813-823. doi:10.1056/NEJMOA2211437/

2.           Weber J et al. NEJM. 2017;377(19):1824-1835. doi:10.1056/NEJMOA1709030

3.           Eggermont AMM et al. NEJM. 2018;378(19):1789-1801. doi:10.1056/NEJMOA1802357

4.           Lao CD. Am Soc Clin Oncol Educ Book. 2022;42(42):1-7. doi:10.1200/EDBK_351153

5.           Faries MB et al.  NEJM. 2017;376(23):2211-2222. doi:10.1056/NEJMOA1613210/

6.           Morton DL et al. NEJM. 2014;370(7):599-609. doi:10.1056/NEJMOA1310460/

7.           Welch HG et al. NEJM. 2021;384(1):72-79. doi:10.1056/NEJMSB2019760/

8.           Michielin O et al.   Ann Oncol. 2019;30(12):1884-1901. doi:10.1093/ANNONC/MDZ411

9.           Luke JJ  et al. Lancet. 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1

10.        Long G V  et al. NEJM. 2017;377(19):1813-1823. doi:10.1056/NEJMOA1708539/

11.        Dummer R  et al. NEJM. 2020;383(12):1139-1148. doi:10.1056/NEJMOA2005493/

 

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Show Notes

1. Background, staging and work-up of regional melanoma
2. Evidence for adjuvant and neoadjuvant immunotherapy
3. Adjuvant BRAF/MEK inhibitor 
4. Considerations for stage IIB/IIC disease

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:


1.           Patel SP et al. NEJM. 2023;388(9):813-823. doi:10.1056/NEJMOA2211437/

2.           Weber J et al. NEJM. 2017;377(19):1824-1835. doi:10.1056/NEJMOA1709030

3.           Eggermont AMM et al. NEJM. 2018;378(19):1789-1801. doi:10.1056/NEJMOA1802357

4.           Lao CD. Am Soc Clin Oncol Educ Book. 2022;42(42):1-7. doi:10.1200/EDBK_351153

5.           Faries MB et al.  NEJM. 2017;376(23):2211-2222. doi:10.1056/NEJMOA1613210/

6.           Morton DL et al. NEJM. 2014;370(7):599-609. doi:10.1056/NEJMOA1310460/

7.           Welch HG et al. NEJM. 2021;384(1):72-79. doi:10.1056/NEJMSB2019760/

8.           Michielin O et al.   Ann Oncol. 2019;30(12):1884-1901. doi:10.1093/ANNONC/MDZ411

9.           Luke JJ  et al. Lancet. 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1

10.        Long G V  et al. NEJM. 2017;377(19):1813-1823. doi:10.1056/NEJMOA1708539/

11.        Dummer R  et al. NEJM. 2020;383(12):1139-1148. doi:10.1056/NEJMOA2005493/

 

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology